CYRX · XBRL financial data

Cryoport financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CYRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2020Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	79	223	237	233	228	176
Revenue from contracts with customers	—	—	237	169	228	176
Cost of revenue	42	126	133	134	129	93
Gross profit	36	97	104	99	100	83
Research and development	9	17	16	18	18	17
Selling, general and administrative	57	98	120	147	149	103
Total operating expenses	66	114	136	214	230	120
Operating income (loss)	(30)	(18)	(32)	(115)	(131)	(37)
Interest expense	3	5	6	6	4	2
Other income (expense)	(1)	(3)	(6)	5	(7)	(3)
Income tax expense (benefit)	(0)	2	2	0	1	2
Net income (loss)	(33)	(276)	(37)	(100)	(115)	78
Earnings per share, basic USD per share	(1.94)	(6.18)	(0.93)	(2.21)	(2.49)	1.40
Earnings per share, diluted USD per share	(1.94)	(6.19)	(0.93)	(2.21)	(2.49)	1.40
Weighted average shares, basic millions of shares	39	46	49	49	49	50
Weighted average shares, diluted millions of shares	39	46	49	49	49	50

Fiscal years (CYRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2020Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	37	139	37	46	45	250
Short-term investments	56	490	487	410	216	161
Accounts receivable	31	39	44	42	46	33
Inventory	11	17	28	26	22	23
Prepaid and other current assets	12	9	9	10	12	8
Total current assets	147	694	604	535	342	476
Property and equipment, net	30	49	64	85	89	85
Right-of-use asset	14	21	27	33	47	40
Goodwill	145	147	151	108	52	22
Total assets	552	1,113	1,039	958	703	765
Total current liabilities	35	43	41	46	65	219
Lease liability, non-current	12	18	25	29	44	39
Total liabilities	170	471	483	469	302	262
Accumulated deficit	(192)	(468)	(543)	(642)	(757)	(689)
Total stockholders' equity	383	642	556	489	402	503
Total liabilities and equity	552	1,113	1,039	958	703	765
Common shares outstanding (cover page) millions of shares	46	50	48	49	50	50

Fiscal years (CYRX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2020Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(33)	(276)	(37)	(100)	(115)	78
Stock-based compensation	0	15	20	23	20	10
Depreciation and amortization	10	20	23	27	31	28
Net cash from operating activities	(15)	8	(2)	(1)	(16)	(9)
Purchases of property and equipment	9	24	22	39	17	16
Net cash from investing activities	(382)	(469)	(60)	36	177	250
Proceeds from issuing common stock	28	0	—	—	—	—
Share repurchases	0	0	38	—	—	10
Net cash from financing activities	386	564	(39)	(24)	(162)	(21)
Net change in cash	(10)	102	(103)	10	(1)	205

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cryoport	269	49	1.1*	50.6M	—	Q2 FY26 10-QJun 30, 2026
Capricor Therapeutics	21	not reported	(31)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
REGENXBIO	36	108	(62)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Cronos Group	467	53	24*	368.4M	—	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17	1.4	(18)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268	not reported	(33)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Carisma Therapeutics	2.8	45	1.9*	41.8M	—	Q3 FY25 10-QSep 30, 2025
Theravance Biopharma	220	21	(7)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.